March 27th Options Now Available For Accenture (ACN)

The piece outlines option income strategies for Accenture (ACN), where the stock trades at $238.96: selling a $235 put at an $11.00 bid would obligate purchase at $235 but net a $224 effective cost basis, with a 58% probability of expiring worthless and a 4.68% return (34.20% annualized) on cash at risk. Conversely, selling a $245 covered call at an $11.90 bid (March 27 expiration) would cap upside at $245 but generate a 7.51% total return if called, with a 52% chance it expires worthless and a 4.98% yield boost (36.38% annualized). Implied vols are ~43% (put) and ~46% (call) versus a trailing 12-month realized volatility of 31%, with Stock Options Channel tracking odds and contract histories on its site.

Analysis

Market structure: The option quotes imply clear winners are option premium sellers and income-oriented ACN holders — short $235 puts (receive $11) or covered-call sellers collect ~4.7–5.0% gross to March 27 (annualized 34–36%). Corporates and competitors are largely unaffected structurally, but delta-hedging from concentrated option selling could create short-term directional flows into ACN if put sellers are forced to buy stock or dealers hedge. The 14–15 percentage-point gap between implied vol (43–46%) and realized TTM vol (31%) signals risk premia for volatility sellers in the near term.

Risk assessment: Tail risks include a large client win/loss, material guidance cut or macro spending slump that could drop ACN >10–15% (assignment risk on sold puts); regulatory/procurement shocks in major markets (EU/UK) are low-probability but high-impact. Timeframes matter: immediate (days) option theta decay; short-term (weeks to Mar 27) option premium capture; long-term (quarters) business fundamentals driven by bookings and FX. Hidden dependencies include large-account concentration and backlog recognition timing which can swing EPS by multiple cents per share; catalysts are upcoming earnings, large contract announcements, and US/Europe macro PMIs.

Trade implications: Direct trade = tactical income: sell cash-secured Mar27 $235 puts sized to 1–2% portfolio (target acquisition cost $224) or sell $245 covered calls if willing to cap upside to $245 for +7.5% through expiry. Risk-defined alternative = sell $235/$220 put spreads to collect reduced credit while capping max assignment; consider buying protective puts (e.g., Mar27 $225) if long stock. Pair trade = long ACN vs short CTSH (1:1) for 3–6 months to exploit scale/contracting resilience; hedge size so net delta ~0.

Contrarian angle: Consensus income chase underestimates conditional assignment risk — selling naked puts is attractive only if you want to own ACN at $224 and are comfortable with 10–15% drawdowns. Implied vol premium is likely to compress on any benign earnings, producing fast gains for volatility sellers but also rapid losses if IV jumps on negative guidance. Historical parallel: post-earnings IV-rich names often print quick 3–8% mean reversion into expiry; large put-selling concentrations can create crowded long positions if defaults/assignments occur.

Key Decisions for Investors

• Sell cash-secured ACN Mar 27 $235 puts sized to 1–2% of total portfolio notional (collect ~$11, effective buy price $224). Set hard rule: buy-to-close if ACN falls below $215 or if IV increases >10 percentage points vs today.
• If already long ACN, sell Mar 27 $245 covered calls for ~11.90 to harvest ~7.5% through expiry; size such that called-away outcome is acceptable and buy-to-close if ACN > $260 before expiry or after positive earnings print.
• If wanting defined risk, sell Mar 27 ACN $235/$220 put spread (cash-secured) sized to 1–3% portfolio to collect reduced credit while capping assignment exposure; roll/adjust if spread width loss exceeds 50% of max loss.
• Establish a 3–6 month pair trade: long ACN / short CTSH (1:1) sized to 0.5–1.5% portfolio delta-neutral exposure to capture relative resilience; exit if ACN/CTSH spread moves unfavorably >6% or on ACN revenue guide cut >1 percentage point.